Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (21-30 of 201) with videos related to

Pageof 21
Sort By:
Gynecologic Oncology|October 27, 2009
Trial design for evaluation of novel targeted therapiesJohn Farley, Peter G Rose
Gynecologic Oncology Reports|October 26, 2019
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencingPeter G Rose, Anne Sierk
Surgical Oncology Clinics of North America|April 9, 2005
Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technologyRobert Kim, Peter G Rose
Women'S Health (London, England)|October 7, 2009
Role of gemcitabine in the treatment of ovarian cancerFadi Abushahin, Peter G Rose
Gynecologic Oncology|November 25, 2010
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?Peter G Rose, Mark F Brady
Expert Opinion on Pharmacotherapy|August 21, 2002
Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a reviewPeter G Rose, Panos T Lappas
Expert Review of Anticancer Therapy|July 5, 2018
Management Strategies for Recurrent Endometrial CancerElizabeth V Connor, Peter G Rose
Expert Opinion on Pharmacotherapy|December 1, 2005
Docetaxel in ovarian cancerPedro F Escobar, Peter G Rose
Gynecologic Oncology Reports|September 8, 2025
The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case seriesAndreea I Dinicu, Peter G Rose
International Journal of Nanomedicine|August 28, 2007
Pegylated liposomal doxorubicin in ovarian cancerAndrew E Green, Peter G Rose
Pageof 21

Showing results (21-30 of 201) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology|October 27, 2009
Trial design for evaluation of novel targeted therapiesJohn Farley, Peter G Rose
Gynecologic Oncology Reports|October 26, 2019
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencingPeter G Rose, Anne Sierk
Surgical Oncology Clinics of North America|April 9, 2005
Surgical staging of gynecologic malignancies: the role of laparoscopy and sentinel node technologyRobert Kim, Peter G Rose
Women'S Health (London, England)|October 7, 2009
Role of gemcitabine in the treatment of ovarian cancerFadi Abushahin, Peter G Rose
Gynecologic Oncology|November 25, 2010
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?Peter G Rose, Mark F Brady
Expert Opinion on Pharmacotherapy|August 21, 2002
Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a reviewPeter G Rose, Panos T Lappas
Expert Review of Anticancer Therapy|July 5, 2018
Management Strategies for Recurrent Endometrial CancerElizabeth V Connor, Peter G Rose
Expert Opinion on Pharmacotherapy|December 1, 2005
Docetaxel in ovarian cancerPedro F Escobar, Peter G Rose
Gynecologic Oncology Reports|September 8, 2025
The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case seriesAndreea I Dinicu, Peter G Rose
International Journal of Nanomedicine|August 28, 2007
Pegylated liposomal doxorubicin in ovarian cancerAndrew E Green, Peter G Rose
Pageof 21